What type of paralysis is associated with the use of agonist (depolarizing) neuromuscular blockers?

The use of agonist (depolarizing) neuromuscular blockers is associated with flaccid paralysis. These agents, such as succinylcholine, work by binding to the nicotinic acetylcholine receptors at the neuromuscular junction and causing an initial depolarization of the muscle membrane. However, this is followed by a persistent depolarization that prevents further muscle contractions, leading to muscle relaxation.

Flaccid paralysis is characterized by a loss of muscle tone and strength, causing the affected muscles to become relaxed and unable to contract effectively. This contrasts with spastic paralysis, which involves increased muscle tone and spasms due to abnormal muscle contraction. Therefore, the correct association of agonist neuromuscular blockers with flaccid paralysis highlights their mechanism of action, where sustained receptor activation leads to muscle inactivation rather than continuous contraction.